Literature DB >> 35115805

Novel Insights into the Emerging Role of Neat1 and Its Effects Downstream in the Regulation of Inflammation.

Yongli Pan1,2, Ting Wang3, Zhiqiang Zhao4, Wei Wei2,5, Xinyu Yang6, Xianbin Wang7, Wenqiang Xin2,6.   

Abstract

Nuclear paraspeckle assembly transcript 1 (Neat1) located at chromosome 11 is a long non-coding RNA that is widely expressed in mammalian cell types, and which is overexpressed in several inflammation-related disorders. Inflammation implies a plethora of mutual interactions between both soluble factors and cells due to various stimuli including tissue injury. Although there is no doubt that inflammation is critically involved in multiple biological and pathological processes alike, the precise mechanisms being involved are still open for debate. In this context, the role of Neat1 as a regulator of inflammation, microglial activation, and lipid accumulation under various inflammatory conditions remains elusive. Herein, we review the regulation of Neat1 and how it modulates the expression of its target genes. Thereafter, we will review the impact of Neat1 on inflammation by activating or inhibiting various signaling pathways, such as microRNAs, AKT, TLR4, TRAF6, and NF-κB.
© 2022 Pan et al.

Entities:  

Keywords:  NF-κB; Neat1; inflammation; lipids; microRNA; microglia

Year:  2022        PMID: 35115805      PMCID: PMC8802408          DOI: 10.2147/JIR.S338162

Source DB:  PubMed          Journal:  J Inflamm Res        ISSN: 1178-7031


Introduction

Inflammation is an adaptive pathological response initiated after bacterial or viral infection,1,2 and it is a normal defense mechanism that the body uses to protect itself from tissue injury. In response to these stimuli, immune cells migrate to the site of infection and/or injury prompting tissue repair/wound healing.3 Thus, it is necessary to understand the mechanisms under the inflammation so that we can seek effective anti-inflammatory resolutions.4 However, up to now, our understanding of inflammation is largely based on the central dogma of molecular biology.5 Long non‐coding RNAs (lncRNAs) are defined as a class of RNA transcripts with a length of longer than 200 nucleotides, by far the largest fraction of non-coding transcripts,6,7 which can be transcribed from different genomic regions including intergenic regions, mitochondrial regions, specific chromosomal regions, and intergenic.8,9 Nuclear paraspeckle assembly transcript 1 (Neat1), a nuclear lncRNAs, a vital component of paraspeckles, plays critical roles in multiple cellular physiology and pathophysiology,10,11 such as the innate immune reaction,12 organ development,13,14 cancer15–17 and neurodegenerative diseases.18–21 There are two isoform transcripts of Neat1, Neat1_1 (3.7 kb) and Neat1_2 (23 kb), respectively, both of which are localized to nuclear paraspeckles.22 Paraspeckles are a type of subnuclear body built on the Neat1 and enriched with various proteins, RNAs, which are involved in regulating gene expression by a process called nuclear retention.23 Accumulating evidence has shown that Neat1is dysregulated during the progression of a variety of diseases. For example, Zhou et al and Zhang et al found that Neat1 is aberrantly expressed in glioma and colorectal cancer, while its expression is closely related to tumor cell viability, migration, and invasion, as well as for the overall patient survival.24,25 Neat1 dysregulation has also been shown to be involved in non-cancerous diseases, for instance, Huntington’s Disease (HD), Parkinson’s disease (PD), multiple sclerosis and Hantavirus infection.26 Sunwoo et al identified upregulation of Neat1 in the human HD brain and revealed the neuroprotective function without the precise mechanism in HD pathogenesis.20 Likewise, 1-Methyl-4-phenylpyridinium (MPP+) induced PD was protected by the knockdown of Neat1, and the protect mechanism might relate to α-synuclein expression.27 Notably, the role and mechanism of Neat1 in disorders related to the inflammatory cytokines and mediators are poorly understood and have not been systematically reviewed. Herein, in this study, we discuss and summarize the function and mechanism of Neat1 specific to inflammation and propose potential signaling pathways.

The Course of Inflammation

Inflammation is programmed progress initiated to protect tissue from injury stimuli, which can cause the release of pathogen or danger-associated molecular patterns (PAMP), and promote tissue recovery via suppressing bacteria, viruses, toxins, and infections by fighting pathogens.28–30 Inflammatory responses have the potential to initially inhibit the release of inflammatory mediators, which appear when with an insult and elapse once the injury is eliminated.30,31 Upon the initial stage of the inflammatory response, PAMPs can be identified by macrophages or mast cells, which in turn promote the release of a pro-inflammation-related mediator such as cytokines, chemokines, and eicosanoids, therefore, enhancing vascular permeability and activating the immune response.1,31,32 Besides that, the neutrophils and monocytes immediately move to the lesion region by a series of pathways and molecules like cytokines and adhesion molecules.32 With the signs of progress of inflammation, monocytes and lymphocytes are recruited and migrate to the lesion site to eliminate the harmful substances, which are finally cleared by macrophages through the cell apoptosis pathway.31 When it comes to the final stage of inflammation, the inflammatory process is replaced by the tissue repair process. In addition, inflammatory reaction normally involves the rapid induction of pro-inflammatory response, closely followed by an anti-inflammatory process.33 To regain homeostasis, resolution of inflammation represents a turning point, since the progression from acute-resolving to persistent-chronic inflammation can appear due to a failure in resolving inflammatory processes.33 Herein, for the sake of promoting tissue to restore homeostasis, the inflammatory reaction must be immediately inhibited to prevent the organ from further damage,31 and a great deal of signal pathways is included in the inflammatory process, providing novel insight into the treatment of inflammation-related disorders.

The Course of Neat1

Although ncRNAs do not encode for proteins, they participate in various biological processes and thus play a vital role in transcriptional and post-transcriptional modulation.34,35 They can be divided into two categories according to the length of the RNA chain, involving lncRNA with lengths of more than 200 nucleotides and small ncRNAs with lengths of less than 200 nucleotides.35,36 Discovered in 2007 by Hutchinson et al,37 Neat1 lncRNA is––as indicated in the name, nuclear enriched abundant transcript–– one of the most abundant lncRNAs localized within paraspeckles in the mammalian nucleus and abundantly expressed in a variety of cell types.38–40 Additionally, it is suggested that Neat1 can target numerous genomic regions in various cells, mainly involving active genes, revealing that it is a regulator for plenty of active genes and signal pathways.41 Structured illumination microscopy detecting RNA and protein components of paraspeckles simultaneously revealed the structural arrangement of Neat1 within paraspeckles; that is, the paraspeckle compositions are located at the core-shell spheroidal structure; however, Neat1’, 5’ and 3’ ends are in paraspeckle around, and the central sequence is present at the core site.42,43 Paraspeckle is a complex consisting of subnuclear ribonucleoprotein within interchromatin, which plays a vital role in modulating transcription and RNA processing mainly via regulating RNA and protein editing and serving as a sponge targeting to various microRNAs.19 There are two subtypes of mono-exonic isoforms transcribed from the Neat1 locus from chromosome 11, known as shorter Neat1_1 with 3684 nucleotides and longer Neat1_2 with 22,743 nucleotides.19,44 The shorter Neat1_1 isoform (3.7 kb in human) is polyadenylated,23 whereas the longer 23 kb subtype of Neat1_2 is not polyadenylated. Neat1_1 is high abundance and exhibits a high expression in a wide range of tissues.19 Nonetheless, in contrast to the Neat1_2 isoform, the shorter Neat1_1 isoform has no an integral element of paraspeckles; however, it appears as microspeckles and thus may contain other effects that have not been discovered.43 Additionally, Sasaki et al45 indicated that the knockdown of the production of Neat1_2 can lead to paraspeckle elimination even in the presence of intact Neat1_1. Likewise, Neat1_2 defect female mice have a loss function of reproductive tissue development; however, no external or histological abnormalities are observed in Neat1_1 knockout mouse.13,46

NEAT1 Directly Regulates Inflammation in the Central Nervous System

Inflammatory response, in the central nervous system (CNS), is generally recognized as an essential component of the CNS to restrain abnormal protein aggregates, infection, ischemia, and toxins.47,48 Neat1 has been identified as dysregulated in cell growth, differentiation, apoptosis, cells migration, metastasis, and invasion in neurological disorders,26,49 where regulation of inflammation plays a vital role. Although the fundamental role of Neat1 in terms of inflammation in CNS is becoming increasingly evident,50,51 it is urgent to summarize the inflammatory effect of Neat1 upon inflammatory conditions of the CNS owing to diverse interaction pathways in various neurological disorders with disparate efficiency. The electronic databases, including Cochrane Library, Medline, PubMed, Embase, ScienceDirect, and other databases were retrieved to identify the literature exploring the regulation of Neat1 on inflammation upon various neurological diseases from the inception of electronic databases to September 2021. We retrieved studies using the following keywords in accordance with Boolean logic: (“Neat1” OR “nuclear paraspeckle assembly transcript 1”) AND (“inflammatory” OR “inflammation” OR “microglia”). Beyond this, research on the appraisal reference list was manually checked to determine other potential qualification trials that may have been missed by the database searches. The process was iterated until no more publications would be obtained. A total of 15 publications were identified in this section,50–64 which were performed between 2017 and 2021. The most widely used species and related inflammatory models are mice and middle cerebral artery occlusion (MCAO), respectively. The most common identification method and inflammatory markers are quantitative real-time polymerase chain reaction and interleukin, respectively. Of these 15 studies, 5 on stroke, 6 on PD, 2 on spinal cord injury (SCI), and 1 on traumatic brain injury with the last one on epilepsy study, suggesting that it is sufficient to illustrate that Neat1 can modulate inflammation in the CNS disorders. Up on stroke condition, an upregulation of Neat1 was uncovered in ischemic stroke patients’ blood,61 animals with an MCAO,60 and in vitro cells with hypoxia.50 Similarly, the upregulation of Neat1 has a detrimental effect and accelerates disease progression in PD via regulating inflammation.19 Moreover, the knockdown of Neat1 could inhibit microglia polarization towards the M1 phenotype in various neurological disorders.62 Nevertheless, concerning the differences between diseases (dosage and delivery time), the studies used heterogeneous experimental paradigms meeting their own applied study purposes. More details are shown in Table 1.
Table 1

Preclinical and Clinical Studies Assessing the Effect of NEAT1 on the Regulation of Inflammation in Central Nervous System

Author, YearDisease’s TypeDiseases ModelOrganismExpressionIdentifyInflammatory MarkerMechanismRef.
Han et al 2019StrokeOGD/RCellsUpqRT-PCRIL-1β, 6, TNF-αWnt/β-catenin[50]
Li et al 2020StrokePatientsHumanUpqRT-PCRTNF-α, IL-1β, 6, 8, 10, 17, 22miR-124, miR-125a[61]
Ni et al 2020StrokePatients, OGD/RHuman, CellsUpqRT-PCRNAAKT/STAT3[62]
Zhang et al 2021StrokeMCAO, OGD/RRats, CellsUpqRT-PCRIL-1β, 18miR-22-3p[59]
Jin et al 2021StrokeMCAOMiceUpqRT-PCRTNF-α, IL-1β, 6, NF-κBNA[60]
Ban et al 2020SCILPS treatCellsUpqRT-PCRIL-1β, 6, 10, TNF-αmiR-29a/BCL2L11[57]
An et al 2021SCILPS treatCellsUpqRT-PCRIL-1β, 6, TNF-αmiR-211-5p/MAPK1[58]
Xie et al 2019PDMPP+ treatCellsUpqRT-PCRIL-1β, 6, TNF-αmiR-124[54]
Zhou et al 2020PDMPP+ treatCellsUpqRT-PCRIL-1β, 6, TNF-αmiR-1277-5p/ARHGAP26[55]
Liu et al 2020PDMPTP, MPP+ treatMice, CellsUpqRT-PCRIL-1β, 6miR-212-3p/AXIN1[56]
Liu et al 2020PDMPP+ treatCellsUpqRT-PCRIL-1β, TNF-αmiR-212- 5p/RAB3IP[51]
Chen et al 2021PDMPP+ treatCellsUpqRT-PCRIL-1β, 6, TNF-αmiR-124-3p/PDE4B/mTOR[52]
Sun et al 2021PDMPP+ treatCellsUpqRT-PCRIL-1βmiR-1301-3p[53]
Zhong et al 2017TBIOGD/R, ICVI AVVMice, CellsUpChIP-qPCRIL-1, TNF-αPidd1[63]
Wan et al 2020EpilepsyPatients, IL-1β treatHuman, CellsUpqRT-PCRIL-1β, 6, TNF-αmiR-129-5p/notch[64]

Abbreviations: NA, not available; qRT-PCR, quantitative real-time polymerase chain reaction; IL, interleukin; TNF, tumor necrosis factor; OGD/R, oxygen-glucose deprivation/re-oxygenation; MCAO, middle cerebral artery occlusion; AIS, acute ischemic stroke; AKT, protein kinase B; STAT3, signal Transducer And Activator Of Transcription 3; NF-κB, nuclear factor-κB; SCI, spinal cord injury; LPS, lipopolysaccharides; BCL2L11, Bcl-2-like protein 11; MAPK1, mitogen-activated protein kinase 1; PD, Parkinson’s disease; AXIN1, axis inhibition protein 1; MPTP, 1-methyl- 4-phenyl-1, 2, 3, 6-tetrahydropyridine injection; MPP+, 1-methyl- 4-phenyl pyridine; RAB3IP, RAB3A-interacting protein; PDE4B, phosphodiesterase 4B; mTOR, mechanistic target of rapamycin; TBI, traumatic brain injury; ICVI, intracerebroventricular injection; AVV, adenovirus; ChIP-qPCR, chromatin immunoprecipitation polymerase chain reaction; Pidd1, p53-induced death domain-containing protein 1.

Preclinical and Clinical Studies Assessing the Effect of NEAT1 on the Regulation of Inflammation in Central Nervous System Abbreviations: NA, not available; qRT-PCR, quantitative real-time polymerase chain reaction; IL, interleukin; TNF, tumor necrosis factor; OGD/R, oxygen-glucose deprivation/re-oxygenation; MCAO, middle cerebral artery occlusion; AIS, acute ischemic stroke; AKT, protein kinase B; STAT3, signal Transducer And Activator Of Transcription 3; NF-κB, nuclear factor-κB; SCI, spinal cord injury; LPS, lipopolysaccharides; BCL2L11, Bcl-2-like protein 11; MAPK1, mitogen-activated protein kinase 1; PD, Parkinson’s disease; AXIN1, axis inhibition protein 1; MPTP, 1-methyl- 4-phenyl-1, 2, 3, 6-tetrahydropyridine injection; MPP+, 1-methyl- 4-phenyl pyridine; RAB3IP, RAB3A-interacting protein; PDE4B, phosphodiesterase 4B; mTOR, mechanistic target of rapamycin; TBI, traumatic brain injury; ICVI, intracerebroventricular injection; AVV, adenovirus; ChIP-qPCR, chromatin immunoprecipitation polymerase chain reaction; Pidd1, p53-induced death domain-containing protein 1.

Neat1 Directly Regulates Inflammation in the Peripheral System

Peripheral inflammation is a non-specific, adaptive response to infections or noxious stimuli aiming to limit injury and enhance recovery.65 Systemic inflammation is characterized by an up-regulated expression of circulating cytokines, chemokines, and acute-phase proteins, as can be seen in multiple chronic disorders, such as obesity, diabetes, and metabolic syndrome, can lead to serious health risks.66 It is of interest that peripheral inflammatory stimuli that circulate in the blood may lead to the release of cytokines in the CNS mainly via regulating the integrity of the blood–brain barrier and activation of microglia,67,68 suggesting that peripheral and central inflammation can be mutually modulated.65 Indeed, Neat1 can regulate inflammation in CNS; therefore, the effect of Neat1 on peripheral inflammation deserves more attention. The aforementioned literature search strategy with the keywords of “Neat1” OR “nuclear paraspeckle assembly transcript 1” was also applied in this section and yielded a total of 53 studies,69–121 suggesting broad regulatory effect of Neat1 on peripheral inflammation. Sepsis is a systemic inflammatory response syndrome triggered by infection, with a global incidence of approximately 437 per 100,000 person-years.70 Ten of these included studies, respectively, demonstrated that circulating Neat1 correlated with an increased risk of sepsis, elevated severity, and unfavorable prognosis, as well as higher expression of pro-inflammatory cytokines in sepsis patients, and knockdown of Neat1 promoted viability and reduced the expression of inflammatory cytokines in lipopolysaccharide (LPS)-induced cells.69–78 Additionally, inflammation is a vital driver of atherosclerosis and myocardial infarction, and besides various proteins and microRNAs, Neat1 has been involved in inflammation regulation.79–85 Fu et al,83 Chen et al,84 and Wang et al85 indicated that silencing of Neat1 can suppress lipid uptake inflammation-related molecules including interleukin (IL)‐6, reactive oxygen species, IL‐1β, and tumor necrosis factor (TNF)‐α. Meanwhile, Gast et al79 applied a Neat1 -/- mice and showed the first direct illustration that Neat1 was involved in the regulation of T cell and monocyte-macrophage lineage differentiation and functions via serving as a novel lncRNA-type immunoregulator in myocardial infarction. The characters and primary mechanism of some of these studies are summarized in Table 2, demonstrating Neat1 may offer a promising strategy to treat the disorders with peripheral inflammation.
Table 2

Preclinical and Clinical Studies Assessing the Effect of NEAT1 on the Regulation of Inflammation in Peripheral System

Author, YearDiseasesModelOrganismExpressionIdentificationInflammatoryMain ActionRef.
MethodMarkerMechanism
Xia et al 2020SepsisLPSMice, CellsUpqRT-PCRTNF-α, IL-6, 10, MCP-1miR-211/PI3K/AKT[69]
He et al 2019SepsisPatientsHumanUpqRT-PCRTNF-α, IL-1β, 6, 17miR-124[71]
Huang et al 2018SepsisPatientsHumanUpqRT-PCRCRP, TNF-α, IL-1β, 6, 8, 10NA[70]
Chen et al 2019SepsisCLPMiceUpqRT-PCRTNF-α, IL-1β, 6miR-125/MCEMP1[72]
Liu et al 2020SepsisPatients, LPSHuman, CellsUpqRT-PCRTNF-α, IL-1β, 6, 9miR‐590‐3p[74]
Wu et al 2020SepsisPatients, LPSHuman, CellsUpqRT-PCRTNF-α, IL-1β, 6, 8miR-370-3p/TSP-1[76]
Xiao et al 2020SepsisPatients, LPSHuman, CellsUpqRT-PCRTNF-α, IL-1β, 6, 8miR-370-3p/Irak2[77]
Yang et al 2021SepsisLPSCellsUpqRT-PCRTNF-α, IL-1β, 6miR-31-5p/POU2F1[78]
Li et al 2020SepsisPatients, LPSHuman, CellsUpqRT-PCRTNF-α, IL-1β, 6miR-17-5p/TLR4[73]
Wang et al 2020SepsisLPSCellsUpqRT-PCRTNF-α, IL-1β, 4, 6, 10miR-125a-5p/TRAF6/ TAK1[75]
Chen et al 2020MIAs2O3CellsUpqRT-PCRTNF-α, IL-1β, 6miR-124/NF-κB[80]
Gast et al 2019MIPatients, LPSHuman, Mice, CellsUpRNA-sequencingTNF-α, IL-6, 10, IFN-γ,NA[79]
Wang et al 2019MILPSMiceUpqRT-PCRTNF-α, IL-1, 6, MCP1TLR2/NF-κB[81]
Wei et al 2020MILPSCellsUpqRT-PCRTNF-α, IL-1β, 6miR-144-3p[82]
Liu et al 2019OAPatientsHuman, CellsUpqRT-PCRTNF-α, IL-1β, 6, 8miR‐193a‐3p/SOX5[105]
Wang et al 2019OAPatientsHuman, CellsUpqRT-PCRTNF-α, IL-1β, 6, 8, COX-2miR-181a/GPD1L[106]
Tu et al 2019OAPatients, IL-1βHuman, CellsUpqRT-PCRIL-1βmiR-377-3p/ITGA6[107]
Wang et al 2017OAPatientsHuman, CellsUpqRT-PCRIL-6, 8miR-181c[110]
Huang-Fu et al 2018ASox-LDLCellsUpqRT-PCRNF-κBCD36, p65[83]
Chen et al 2018ASox-LDLCellsUpqRT-PCRTNF-α, IL-1β, 6miR-128[84]
Wang et al 2018ASox-LDLCellsUpqRT-PCRTNF-α, IL-1β, 6, COX-2miR‐342‐3p[85]
Guo et al 2019ASPatients, ox-LDLHuman, CellsUpqRT-PCRTNF-α, IL-1β, 6miR-30c-5p/TCF7[91]
Feng et al 2020AKIPatients, LPSHuman, CellsUpqRT-PCRTNF-α, IL-1β, 6, 8miR-22-3p[93]
Gao et al 2020AKIPatients, LPSHuman, CellsUpqRT-PCRTNF-α, IL-1β, 6let-7b-5p/TRAF6[102]
Wang et al 2020AKISepsis-induced AKI, LPSRats, CellsUpqRT-PCRTNF-α, IL-1β, 6miR-27a-3p/TAB3[94]
Wang et al 2018IBDAcute colitisMiceUpBioinformaticsTNF-α, IL-7, 12a, 17amiR204-5p-PI3K-AKT[89]
Liu et al 2018IBD5% DSSMice, Rats, CellsUpqRT-PCRTNF-α, IL-23Polarization of macrophages[90]
Pan et al 2021IBDPatients, DSS, TNF-αHuman, Mice, CellsUpqRT-PCRIL-8, TNF-α, MCP1TNFSF1B[112]
Zhou et al 2020ALISepsis-evoked ALI, LPSMice, CellsUpqRT-PCRTNF-α, IL-1β, 6HMGB1-RAGE[86]
Chen et al 2020ALILPSMice, CellsUpqRT-PCRTNF-α, IL-1β, 6miR-944/TRIM37[101]
Zhang et al 2019ALIPatients, LPSHuman, CellsUpqRT-PCRTNF-α, IL-1β, 6Let-7a/TLR4[95]
Li et al 2019AsthmaPatientsHumanUpqRT-PCRTNF-α, IL-1β, 6, 17miR-124[87]
Wang et al 2021AsthmaPDGFCellsUpqRT-PCRIL-4, 6, 13MiR-9-5p/SLC26A2[88]
Zhang et al 2016SLEPatients, LPSHuman, CellsUpqRT-PCRTNF-α, IL-6MAPK[103]
Zhang et al 2019SLELPSCellsUpqRT-PCRTNF-α, IL-1β, 6, IFN-γmiR-146b/TRAF6/NF-κB[104]
Wang et al 2020RAPatients, TNF-αHuman, CellsUpqRT-PCRTNF-αmiR-410-3p/YY1[119]
Rao et al 2021RABovine type II collagenMice, CellsUpqRT-PCRTNF-α, IL-1β, 6miR-23a/MDM2/SIRT6[120]
Shao et al 2020DRPatients, diabetic animalHuman, Rats, CellsUpqRT-PCRCOX-2, TNF-α, IL-6TGF‐β1, VEGF[92]
Li et al 2020Renal fibrosisUUO, TGF-β1Mice, CellsUpqRT-PCRIL-1β, 6miR-129[111]
Jin et al 2019NAFLDFree fatty acidCellsUpqRT-PCRTNF-α, MCP1, IL-1β, 6miR-506/GLI3[96]
Ye et al 2020ASHPatientsHuman, Mice, CellsUpqRT-PCRTNF-α, IL-1β, 6miR-129-5p/SOCS2[97]
Wang et al 2021ALFPatients, D-galactosamineHuman, MiceUpqRT-PCRTNF-α, IL-1β, 6miR-139/PUMA[98]
Xu et al 2019ACLFPatients, LPSHuman, Rats, CellsUpqRT-PCRIL-1, 6, 22TRAF6[99]
Zhang et al 2021NASHMCD dietMice, CellsUpqRT-PCRNF-κBmiR-129-5p/PEG3[100]
Sun et al 2020TBPatients, H37RaHuman, CellsUpqRT-PCRTNF-α, IL-6, IFN-γmiR-377–3p[114]
Sheng et al 2020APCaeruleinMice, CellsUpqRT-PCRTNF-α, IL-6, 10miR-216b/MAP2K6[108]
Zhu et al 2021CSFPatients, OGDHuman, CellsUpqRT-PCRTNF-α, IL-6, sICAM-1miR-148b-3p/ICAM-1[109]
Wang et al 2018HCCTransfectionCellsUpqRT-PCRIL-6IL-6/STAT3[113]
Wang et al 2021I/RI/RCellsUpqRT-PCRTNF-α, IL-1β, 6NA[115]
Wang et al 2021ARPatientsHumanUpqRT-PCRIL-4, 6, 10, 17miR-21, 124, 125a[116]
Nong et al 2019PneumoniaLPSCellsUpqRT-PCRTNF-α, IL-1β, 6, 8miR-193a-3p/TLR4/NF-κB[117]
Dai et al 2021BoneLPSCellsUpqRT-PCRIL-1β, 6NLRP3 inflammasome[118]
Zhan et al 2020DNSTZ, HGRats, CellsUpqRT-PCRIL-1βmiR-34c/NLRP3[121]

Abbreviations: NA, not available; qRT-PCR, quantitative real-time polymerase chain reaction; IL, interleukin; TNF, tumor necrosis factor; PDGF, platelet-derived growth factor; IBD, inflammatory bowel disease; AS, atherosclerosis; MCP-1, monocyte chemoattractant protein-1; DSS, dextran sulfate sodium; HUVECs, human umbilical vein endothelial cells; ox-LDL, oxidized low-density lipoprotein; TCF7, transcription factor 7; UUO, unilateral ureteral obstruction; CRP, C-reactive protein; MCEMP1, mast cell expression membrane protein 1; CLP, cecal ligation and puncture; TSP-1, thrombospondin-1; Irak2, interleukin 1 receptor associated kinase 2; POU2F1, POU domain class 2 transcription factor 1; ALI, acute lung injury; HMGB1, high-mobility group box1; DR, diabetic retinopathy; COX-2, cyclooxygenase‐2; hRECs, human retinal endothelial cells; VEGF, vascular endothelial growth factor; TGF-β1, transforming growth factor-β1; AKI, acute kidney injury; TRAF6, tumor necrosis factor receptor-associated factor 6; TLR4, toll-like receptor 4; NAFLD, non-alcoholic fatty liver disease; ASH, alcoholic steatohepatitis; SOCS2, suppressor of cytokine signaling 2; ALF, acute liver failure; PBMCs, peripheral blood mononuclear cells; PUMA, p53-upregulated modulator of apoptosis; ACLF, acute-on-chronic liver failure; PEG3, paternally expressed gene 3; NASH, non-alcoholic steatohepatitis; MCD diet, methionine choline-deficient diet; NF-κB, nuclear factor-κB; SLE, systemic lupus erythematosus; MAPK, mitogen-activated protein kinase; SLE, systemic lupus erythematosus; IFN-γ, interferon γ; TB, tuberculosis; TRAF6, TRAF6, tumor necrosis factor receptor-associated factor 6; TAK1, transforming growth factor-activated kinase 1; As2O3, arsenic trioxide; MI, myocardial infarction or cardiomyocyte injury; OA, osteoarthritis; SOX-5, sex‐determining region Y‐box protein 5; GPD1L, glycerol-3-phosphate dehydrogenase 1-like; AP, acute pancreatitis; CSF, coronary slow flow; sICAM-1, soluble intercellular adhesion molecule-1; TNFSF1B, tumor necrosis factor superfamily member 1B; HCC, hepatocellular carcinoma; STAT3, signal Transducer And Activator Of Transcription 3; I/R, ischemia/reperfusion; AR, allergic rhinitis; NLRP3, Nod‐like receptor protein 3; RA, rheumatoid arthritis; YY1, Yin Yang1; MDM2, murine double minute-2; SIRT6, Sirtuin 6; DN, diabetic nephropathy; NLRP3, Nod-like receptor protein-3; STZ, streptozotocin; HG, high glucose.

Preclinical and Clinical Studies Assessing the Effect of NEAT1 on the Regulation of Inflammation in Peripheral System Abbreviations: NA, not available; qRT-PCR, quantitative real-time polymerase chain reaction; IL, interleukin; TNF, tumor necrosis factor; PDGF, platelet-derived growth factor; IBD, inflammatory bowel disease; AS, atherosclerosis; MCP-1, monocyte chemoattractant protein-1; DSS, dextran sulfate sodium; HUVECs, human umbilical vein endothelial cells; ox-LDL, oxidized low-density lipoprotein; TCF7, transcription factor 7; UUO, unilateral ureteral obstruction; CRP, C-reactive protein; MCEMP1, mast cell expression membrane protein 1; CLP, cecal ligation and puncture; TSP-1, thrombospondin-1; Irak2, interleukin 1 receptor associated kinase 2; POU2F1, POU domain class 2 transcription factor 1; ALI, acute lung injury; HMGB1, high-mobility group box1; DR, diabetic retinopathy; COX-2, cyclooxygenase‐2; hRECs, human retinal endothelial cells; VEGF, vascular endothelial growth factor; TGF-β1, transforming growth factor-β1; AKI, acute kidney injury; TRAF6, tumor necrosis factor receptor-associated factor 6; TLR4, toll-like receptor 4; NAFLD, non-alcoholic fatty liver disease; ASH, alcoholic steatohepatitis; SOCS2, suppressor of cytokine signaling 2; ALF, acute liver failure; PBMCs, peripheral blood mononuclear cells; PUMA, p53-upregulated modulator of apoptosis; ACLF, acute-on-chronic liver failure; PEG3, paternally expressed gene 3; NASH, non-alcoholic steatohepatitis; MCD diet, methionine choline-deficient diet; NF-κB, nuclear factor-κB; SLE, systemic lupus erythematosus; MAPK, mitogen-activated protein kinase; SLE, systemic lupus erythematosus; IFN-γ, interferon γ; TB, tuberculosis; TRAF6, TRAF6, tumor necrosis factor receptor-associated factor 6; TAK1, transforming growth factor-activated kinase 1; As2O3, arsenic trioxide; MI, myocardial infarction or cardiomyocyte injury; OA, osteoarthritis; SOX-5, sex‐determining region Y‐box protein 5; GPD1L, glycerol-3-phosphate dehydrogenase 1-like; AP, acute pancreatitis; CSF, coronary slow flow; sICAM-1, soluble intercellular adhesion molecule-1; TNFSF1B, tumor necrosis factor superfamily member 1B; HCC, hepatocellular carcinoma; STAT3, signal Transducer And Activator Of Transcription 3; I/R, ischemia/reperfusion; AR, allergic rhinitis; NLRP3, Nod‐like receptor protein 3; RA, rheumatoid arthritis; YY1, Yin Yang1; MDM2, murine double minute-2; SIRT6, Sirtuin 6; DN, diabetic nephropathy; NLRP3, Nod-like receptor protein-3; STZ, streptozotocin; HG, high glucose.

Neat1 Can Regulate the Activation of Microglia

Microglia cells serve as “brain-resident macrophages” that comprise approximately 10% of all the cells in the CNS,122 which play a key role in phagocytic elimination of influencing brain development and maintenance of the neural environment. Normally, the microglia are in the rest state to keep homeostasis in the fields around microglia cells.123 Upon an inflammatory condition, the activation of microglia is the first step of response to inflammation, and then other immune cells like neutrophils, T cells, natural killer cells, and so on were activated in the brain.123–125 Stimuli results in the activation of microglia, which represents the first step of an inflammatory response, followed by four distinct phenotypes, such as ramified, intermediate, amoeboid, and round phenotypes.123,126 Based on the morphological progression and its substance secretion, microglia are characterized as M1-type and M2-type.123 M1-type, the pro-inflammatory phenotype, produces various pro-inflammatory factors such as IL-1β, IL-6, interferon-α, motif chemokine ligand, cyclooxygenase-2, and inducible nitric oxide synthase.123,127–130 M2, anti-inflammatory phenotype, microglia involve the states of both alternative activation and acquired deactivation, which are accompanied by IL-4/IL-13 and IL-10/transforming growth factor (TGF)-β, respectively.123,131,132 Ni et al62 exposed Neat1 knockdown BV-2 cells to oxygen–glucose deprivation/reoxygenation (OGD/R) and then detected the various levels of markers of M1 (CD16, CD32, and CD86) and M2 (BDNF, PDGF, and Arg-1) microglia, demonstrating that Neat1 knockdown suppresses M1microglial polarization but does not promote M2 microglial polarization. Jin et al60 revealed that microglia had shorter ramifies and larger cell bodies after MCAO; however, the antisense oligonucleotides (ASO)-Neat1 group (Neat1 knockdown) was associated with significantly fewer activated microglia. Also, pyknotic nuclei and vacuolated cytoplasm were markedly reduced in the cortex and striatum of ASO-Neat1 mice. Similarly, Han et al50 suggested that Yin Yang 1 (YY1)-induced upregulation of Neat1 contributed to the OGD/R injury and neuroinflammation damage to microglial cells. Neat1 knockdown might therefore contribute to suppressing microglia activation, and information regarding this aspect, however, is scarce.

Neat1 Can Regulate the Expression of Lipids

Lipids are a kind of hydrophobic or amphiphilic small molecules that are insoluble in water and soluble in nonpolar solvents.133 They are an essential structural component of cell membranes and play a vital role in regulating important biological processes that support multiple biological functions, and dysregulation of lipid metabolism has been revealed to be involved in inflammation-related disorders, such as atherosclerosis, cancer, and neurodegenerative diseases.134 Since bioactive lipids emerged as vital factors during all phases of the inflammatory process, we also explored the effect of paraspeckles of Neat1 on lipid uptake. Atherosclerosis has been recognized as a chronic inflammation process induced by lipid accumulation in the vessel wall.135 Neat1 was significantly increased in human macrophages THP‐1 cells incubated with oxidized low-density lipoprotein (ox‐LDL). To investigate the role of Neat1 in foam cells formation, Neat1 was downregulated in THP‐1 cells by transfection of Neat1 small interfering RNA (siRNA), as demonstrated by Wang et al,85 knockdown of Neat1 restrained CD36 protein expression, triglyceride, and oil‐red staining levels, suggesting that Neat1 could modulate the formation of foam cells triggered by ox‐LDL in vitro. Therein, abnormality of triglyceride metabolism is a lipid metabolism disorder and includes hypertriglyceridemia and liver triglyceride accumulation.136 Using rapamycin after transplantation can cause hypertriglyceridemia and liver triglyceride accumulation.137 Fan et al indicated that the down-regulation of the expression of hsa-miR-372–3p contributes to triglyceride accumulation induced by rapamycin, further using dual-luciferase reporter assay and bioinformatics to determine the relationship between hsa-miR-372–3p and Neat1.137 In vivo, Neat1 was upregulated in non-alcoholic fatty liver disease patients, and besides that, knockdown of Neat1 can inhibit lipid accumulation in mice with a high-fat diet.138 Although Neat1 has been illustrated to be collectively effective in regulating lipids and inflammation, information regarding this aspect is scarce. Herein, more evidence-based information is provided in this respect.

Neat1 Correlates with the Level of Inflammatory Cytokines in Clinical Studies

Liquid biopsy is a new diagnostic tool conducted on blood or other biofluids to evaluate the inflammation-derived components and their genomic or proteomic profiles. In clinical practice, it is widely accepted that Neat1 is identified as a potential contributor to the increased secretion of multiple pro-inflammatory factors in diverse inflammatory disorders.103,139 For instance, in patients with systemic lupus erythematosus, the expression level of Neat1 is upregulated in the blood and correlates with the increased expression of pro-inflammatory chemokines and cytokines, such as IL-1β, IL-6, and CXC chemokine ligand 10 (CXCL10), exacerbating the severity of disorder.103 In asthma, Neat1 exhibits the potential to differentiate patients with asthma or not, especially in predicting exacerbation risk and severity of asthma. Neat1 relative expression was positively correlated with TNF-α, IL-1β, and IL-17, while negatively correlated with miR‐124 expression in patients with asthma in exacerbation. Interestingly, miR‐124 relative expression was positively correlated with TNF‐α, IL‐1β, IL‐17, and exacerbation severity as well.87 Likewise, sepsis patients were associated with a higher incidence of plasma Neat1 expression than those in healthy control and further disclosed that Neat1 revealed a good predictive value for sepsis risk and was positively associated with levels of TNF-α, IL-1β, IL-6, and IL-8, while negatively correlated with level of IL-10.74,76 Hence, Neat1 expression is aberrantly-mostly upregulated in inflammatory pathological conditions, indicating that it may serve as a potential diagnostic and prognostic biomarker to monitor disease activity and treatment outcome in multiple inflammatory disorders; however, the potential of Neat1 as a biomarker and as a therapeutic target for clinical CNS inflammation highly warrants further research to elucidate its exact role due to limited clinical data, moreover, different liquid biopsy is deserved to be performed to detect the expression of Neat1 since most studies use blood samples.

The Mechanism of Neat1 in the Effect of Regulating Inflammation

Neat1-miRNA-mRNA Axis is the Key Player in Regulating Inflammation

MicroRNAs (miRNAs) are small non-coding RNAs with lengths of approximately 18–24 nucleotides and can post-transcriptionally modulate gene expression through binding to 3′‐untranslated regions of mRNAs, which further induce degradation or suppression of mRNAs, and then inhibit gene translation.85,140,141 MiRNAs can regulate various target genes via serving as mediators, and one target gene may be regulated by multiple miRNAs.141,142 MiRNAs are involved in crucial cellular functions of inflammatory progression, such as miR‐195 and miR‐146b‐5p, which can regulate inflammatory profile in affecting the crosstalk with smooth muscle cells and foam cell formation via targeting different mRNA, respectively.85 lncRNAs play a key role in multiple human diseases by regulating miRNA since they have direct ‘sponging-like effects’ on miRNAs,141,143 which in turn modulate target genes via imperfect complementarity binding to the 3-UTR of mRNA.141 In addition, some lncRNAs can compete with miRNAs directly through targeting mRNA.140,141 That shows the lncRNA–microRNA–mRNA axis, herein, contributes to the regulation of inflammatory disorders, and the emerging evidence has been identified that the anti- or proinflammatory effects of specific miRNAs are highly modulated by Neat1.114,117 As downstream of Neat1, the top two miRNA reported in frequency were miRNA-124 and miRNA-129 as shown in Table 2. MiR-124, a tumor inhibitor, has recently been reported to be involved in the inhibition of inflammatory responses by diverse pathways, for instance, it plays a crucial role in traumatic brain injury and intestine by regulating inflammation processes and reduces skin inflammation by inhibiting the innate immune response.144–146 Chen et al80 reported that the overexpression of Neat1 markedly increased H9c2 cells inflammation, while the miR-124 could reverse the effects by repressing the NF-κB signaling pathway. With regard to miR-129, Li et al111 uncovered that Neat1 was upregulated, while miR-129 was distinctly downregulated in vitro and in vivo in renal fibrosis models, what is more, Neat1 knockdown and miR-129 overexpression can suppress renal fibrosis, as shown by a decreased expression of inflammatory factor release. Likewise, Zhang et al100 performed the luciferase reporter assay and RNA pull-down and illustrated a direct interaction between miR-129-5p and NEAT1, which in turn interacted with NF-kB signaling pathway. Besides that, Table 2 provides more miRNAs involved in the interaction between Neat1 and inflammatory regulation, hence, a plethora of miRNAs is found in the downstream of Neat1 of which the precise signaling cascades that are regulated under inflammatory conditions are also diverse.

Neat1 Regulates Inflammation Through the NF-κB Pathway

Nuclear factor-kB (NF-κB) is present in almost all types of cells and primarily serves as a transcription factor implicated in various biological processes, such as apoptosis, cell proliferation, tumorigenesis, inflammation, and various autoimmune disorders.147 It is revealed to promote multiple proinflammatory mediators, and suppression of NF-κB signaling correlates with beneficial effects in inflammatory conditions. For instance, LncRNA Snhg8 acts as a competitive endogenous RNA (ceRNA) by binding to miR-425–5p, which was revealed to boost microglial inflammation by targeting the sirtuin1 (SIRT1)‐mediated NF‐κB pathway.148 Furthermore, microglia can mediate experimental autoimmune encephalomyelitis, a neuroinflammatory disorder, and pathogenesis progression, therein, T cells activate the microglial noncanonical NF-κB pathway plays a crucial role.149 As aforementioned, LncRNA can act on mRNA indirectly through miRNA or mRNA, and there is such a relationship between Neat1 and NF‐κB. Xiao et al150 demonstrated that Neat1 was up-regulated in rheumatoid arthritis, a chronic inflammatory disease, and the knockdown of it attenuated TNF-α-induced cell proliferation and inflammatory cytokine production while promoting cell apoptosis by targeting miR-204-5p through activating the NF-κB signaling pathway. Likewise, Nong et al117 indicated Neat1 functioned as a ceRNA by sponging to reversed miR-193a-3p overexpression and alleviated inflammatory injury of normal human fibroblast cell-line WI-38 cells induced by LPS via regulating the activation of NF-κB signaling. Of note, Neat1 is able to interact indirectly with NF-κB via mRNA as well as to regulate inflammation, as indicated by Wang et al that Neat1 knockdown by tail vein injection of siRNAs has the potential to inhibit the expression levels of pro-inflammatory factor by inhibiting the Toll-like receptor 2/NF-κB signaling pathway in myocardial injury.81 Hence, Neat1 appears to interact with NF-κB indirectly via miRNA and mRNA, however, the same signaling pathways that are regulated under other inflammatory conditions (except for the disorders described in the Tables) are not fully known due to currently limited evidence, yet.

Neat1 Regulate Inflammation Through AKT, TLR4, and TRAF6 Pathway

Despite the NF-κB pathway being involved downstream of Neat1, the following question remains: how can Neat1 achieve this pro‐inflammatory effect through the NF-κB signaling pathway? The activation of Toll-like receptor 4 (TLR4)/NF-κB pathway has been widely studied for its involvement in inflammation. It is the main receptor of inflammation and activated in stimuli-challenged macrophages (such as LPS) which further leads to immune cells to release inflammatory cytokines, such as TNF-ɑ, IL-1β, and IL-6, inducing a systemic inflammatory response, followed by the activation of NF-κB.73,117 Zhang et al151 disclosed that Juglanin, a natural compound derived from the crude Polygonum aviculare, could ameliorate LPS induced neuroinflammatory injury through impeding activation of TLR4/NF-κB-mediated inflammatory response, and Neat1 was involved in the TLR4-mediated inflammatory process as identified by Zhang et al.103 Consecutively, Nong et al117 illustrated that knockdown of Neat1 promoted cell viability and ameliorated inflammatory response; besides, it exerted its role through regulating TLR4/NF-κB signaling pathway. TNF receptor-associated factor 6 (TRAF6), an E3 ubiquitin ligase, is a signal transduction molecule shared by the IL-1 receptor/TLR family and the TNFR superfamily.152 To identify that TRAF6 is involved in NF-κB activation, using the TRAF6-deficient mice, Yamamoto et al demonstrated that TRAF6 plays an irreplaceable role in many pathophysiological processes by activating the NF-κB pathway.152 Several previous studies had indicated that down-expression of Neat1 could interact with TRAF6 and decrease its expression level, and significantly inhibited the expression levels of anti-inflammatory cytokines,75,102,104 and Zhang et al104 further hinted that TARF6 could promote the inflammatory injury via activating the NF-κB signaling. Downregulated Neat1 might therefore contribute to suppressing inflammation by regulating TNFR6 and TLR4, which further modulate NF-κB activation. Information regarding this aspect, however, is still scarce. Of note, Akt kinases, also known as protein kinase B, are signaling molecules of cell growth and differentiation and serve as a well-characterized effector of phosphoinositide 3-kinase (PI3K), involved in diverse cellular processes, especially for inflammation.141,153,154 As indicated by Xia et al69 and Wang et al,89 given that Neat1 can modify miRNA/PI3K/AKT axis in cell and animal models exposed to inflammation, it exhibited great potential in inflammatory conditions treatment. Herein, it suggests that pharmacological upregulation of Akt signaling might be a potential target as well for inhibiting inflammation. Besides that, there are, of course, many other pathways that are involved downstream of Neat1 to regulate inflammation as shown in Table 2 and Figure 1.
Figure 1

The overview of mechanisms of how Neat1 regulates inflammation. (A) In the central nervous system, Neat1 can regulate inflammation and the activation of microglia. (B) In the peripheral system, Neat1 can regulate inflammation and liposome deposition. The completion of all the above effects, mainly through the interaction with various miRNA and mRNA, and thus achieve the regulation of inflammation.

The overview of mechanisms of how Neat1 regulates inflammation. (A) In the central nervous system, Neat1 can regulate inflammation and the activation of microglia. (B) In the peripheral system, Neat1 can regulate inflammation and liposome deposition. The completion of all the above effects, mainly through the interaction with various miRNA and mRNA, and thus achieve the regulation of inflammation.

Conclusion

Inflammation usually leads to an aberrant expression of Neat1 that exerts crucial functions in epigenetic and transcriptional regulation of gene expression. The regulation of Neat1 offers a great opportunity for adjuvant treatment of neurological and peripheral disorders, for which inflammation is an excellent target. There is abundant evidence that Neat1 is directly involved in the regulation of inflammation in both the central nervous system and the peripheral system. Furthermore, inhibiting the activation of microglia and accumulation of lipids has practical implications in regulating inflammation, and a great amount of evidence demonstrates that, for now, the regulation of Neat1 appears to suppress microglial activation, lipid accumulation, and inflammatory responses in clinical and preclinical studies. Among the mechanism of Neat1 in the effect of regulating inflammation, the Neat1-miRNA-mRNA network plays a key role, additionally, it can modify various signaling pathways, such as AKT, TLR4, TRAF6, and NF-κB as well.
  154 in total

1.  Long noncoding RNA NEAT1 modulates immune cell functions and is suppressed in early onset myocardial infarction patients.

Authors:  Martina Gast; Bernhard H Rauch; Arash Haghikia; Shinichi Nakagawa; Jan Haas; Andrea Stroux; David Schmidt; Paul Schumann; Stefan Weiss; Lars Jensen; Adelheid Kratzer; Nicolle Kraenkel; Christian Müller; Daniela Börnigen; Tetsuro Hirose; Stefan Blankenberg; Felicitas Escher; Anja A Kühl; Andreas W Kuss; Benjamin Meder; Ulf Landmesser; Tanja Zeller; Wolfgang Poller
Journal:  Cardiovasc Res       Date:  2019-11-01       Impact factor: 10.787

Review 2.  The critical roles of lncRNAs in the development of osteosarcoma.

Authors:  Soudeh Ghafouri-Fard; Zeinab Shirvani-Farsani; Bashdar Mahmud Hussen; Mohammad Taheri
Journal:  Biomed Pharmacother       Date:  2021-02-01       Impact factor: 6.529

3.  Long Non-Coding RNA NEAT1 Regulates Pyroptosis in Diabetic Nephropathy via Mediating the miR-34c/NLRP3 Axis.

Authors:  Jin-Feng Zhan; Hong-Wei Huang; Chong Huang; Li-Li Hu; Wen-Wei Xu
Journal:  Kidney Blood Press Res       Date:  2020-07-28       Impact factor: 2.687

4.  LncRNA NEAT1 regulates the proliferation and production of the inflammatory cytokines in rheumatoid arthritis fibroblast-like synoviocytes by targeting miR-204-5p.

Authors:  Jianwei Xiao; Rongsheng Wang; Weijian Zhou; Xu Cai; Zhizhong Ye
Journal:  Hum Cell       Date:  2021-01-04       Impact factor: 4.174

5.  An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles.

Authors:  Christine M Clemson; John N Hutchinson; Sergio A Sara; Alexander W Ensminger; Archa H Fox; Andrew Chess; Jeanne B Lawrence
Journal:  Mol Cell       Date:  2009-02-12       Impact factor: 17.970

6.  The long noncoding RNA Neat1 is required for mammary gland development and lactation.

Authors:  Laura Standaert; Carmen Adriaens; Enrico Radaelli; Alexandra Van Keymeulen; Cedric Blanpain; Tetsuro Hirose; Shinichi Nakagawa; Jean-Christophe Marine
Journal:  RNA       Date:  2014-10-14       Impact factor: 4.942

7.  Long noncoding RNA NEAT1 correlates with higher disease risk, worse disease condition, decreased miR-124 and miR-125a and predicts poor recurrence-free survival of acute ischemic stroke.

Authors:  Ping Li; Shuyuan Duan; Adan Fu
Journal:  J Clin Lab Anal       Date:  2019-11-12       Impact factor: 2.352

Review 8.  LncRNA NEAT1 in Paraspeckles: A Structural Scaffold for Cellular DNA Damage Response Systems?

Authors:  Elisa Taiana; Domenica Ronchetti; Katia Todoerti; Lucia Nobili; Pierfrancesco Tassone; Nicola Amodio; Antonino Neri
Journal:  Noncoding RNA       Date:  2020-07-01

9.  lncRNA NEAT1 mediates sepsis progression by regulating Irak2 via sponging miR-370-3p.

Authors:  Ting Xiao; Chuihua Sun; Ying Xiao; Yunbao Li
Journal:  Biol Open       Date:  2020-06-24       Impact factor: 2.422

10.  Silencing of Long Non-Coding RNA (lncRNA) Nuclear Paraspeckle Assembly Transcript 1 (NEAT1) Protects PC-12 Cells from LPS-Induced Injury via Targeting miR-29a.

Authors:  Yunchao Ban; Cui Cui
Journal:  Med Sci Monit       Date:  2020-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.